Why Some People Don’t Lose Weight on GLP-1 Drugs: Genetics May Be the Missing Link
GLP-1 weight loss drugs have transformed the treatment of obesity and type 2 diabetes—but they don’t work the same for everyone. While some people experience dramatic weight loss, others see minimal results or struggle with side effects.
Now, new research suggests that your genes could be a key reason why.
A Breakthrough Study on GLP-1 Response
A recent study published in Nature highlights how genetic differences may influence how individuals respond to GLP-1 medications.
Scientists from the 23andMe Research Institute analyzed genetic data from over 15,000 individuals who had taken GLP-1 drugs. Their findings point to specific genetic variations that may determine both effectiveness and side effects.
Why GLP-1 Drugs Don’t Work for Everyone
GLP-1 medications—such as Ozempic and Wegovy—are designed to mimic natural gut hormones that regulate appetite, insulin secretion, and digestion.
Another class of drugs, including Mounjaro and Zepbound, target both GLP-1 and a second hormone pathway known as GIP.
Despite their success, about 10–15% of users are considered “non-responders,” meaning they fail to lose at least 5% of their body weight in clinical trials.
The Genetic Factor: GLP1R and GIPR
The study identified two important genes:
- GLP1R (GLP-1 receptor gene)
- GIPR (GIP receptor gene)
These genes play a direct role in how the body responds to the hormones targeted by these drugs.
Researchers found that:
- A specific variant of the GLP1R gene was linked to greater weight loss
- The same variant also increased the likelihood of nausea and vomiting
- A variant of the GIPR gene was also associated with side effects, especially for people taking dual-action drugs like tirzepatide
In extreme cases, individuals carrying multiple variants had a 15x higher risk of vomiting.
How Much Difference Do Genes Make?
While the differences may seem modest, they are still meaningful:
- One copy of the GLP1R variant → ~1.5 pounds additional weight loss
- Two copies → 3+ pounds additional weight loss
Experts say that, in some cases, this accounted for over 10% of total weight loss, which can be clinically significant.
The Rise of Precision Medicine in Obesity
This research is part of a broader shift toward personalized medicine, where treatments are tailored to an individual’s biology.
Instead of relying on trial and error, doctors may soon use genetic insights to:
- Predict whether a patient will respond to GLP-1 drugs
- Estimate potential weight loss outcomes
- Identify risk of side effects before treatment begins
According to experts, this approach could save patients time, money, and frustration.
What Experts Are Saying
Scientists and clinicians are increasingly recognizing that GLP-1 drugs are not universally effective.
Researchers emphasize that genetics is just one piece of the puzzle, alongside factors like:
- Age
- Sex
- Existing health conditions
- Lifestyle habits
Still, the findings highlight the growing importance of pharmacogenomics—using genetic data to guide medication choices.
What This Means for You
If you’re taking GLP-1 medications and not seeing results, it doesn’t necessarily mean you’re doing something wrong. Your body’s genetic makeup may be influencing how the drug works.
As research evolves, genetic testing could soon help determine:
- Which medication is best for you
- Whether you’re likely to respond
- How to minimize side effects
The Bottom Line
GLP-1 drugs remain a powerful tool in the fight against obesity—but they’re not one-size-fits-all. This new study underscores the role of genetics in shaping treatment outcomes and moves us closer to a future of truly personalized weight loss solutions.
